Argenx stock holds near records after Jefferies reiterates Buy

Published on 09/19/2026 at 12:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Jefferies kept Argenx stock at Buy with a USD 1,215 target on September 16, 2026. The shares closed at USD 999.06 on September 17, 2026.

Fotorealistisches Laborpanorama: Wissenschaftler in weißen Kitteln begutachten leuchtende Antikörper-3D-Modelle auf Bildschirmen, Stahltische mit Laborgeräten im Hintergrund — Argenx NL0010832176 Forscher analysieren im modernen Biopharma-Labor leuchtende Antikörper-Strukturen auf großen Monitoren, Illustration mit AI erstellt.

Argenx stock (NL0010832176) closed at USD 999.06 on Nasdaq on September 17, 2026, with a 52-week range of USD 661.85 to USD 1,072.75 and a market capitalization of USD 62.50 billion.

Jefferies keeps its view

As ad hoc news reported on September 18, 2026, Jefferies reiterated a Buy rating and left its Argenx target at USD 1,215. The same update said the shares were about 17.2 percent below that level.

MarketBeat's September 19, 2026 update said Argenx's average rating was Moderate Buy, with a consensus target of USD 1,158.61 and 24 analysts covering the name. It also showed a trailing P/E of 38.22 and a net margin of 32.19 percent.

Quarter still carries weight

According to MarketBeat on September 19, 2026, Argenx reported EPS of USD 7.32 and revenue of USD 1.54 billion for the quarter ended July 21, 2026. Those figures topped the consensus estimates of USD 5.86 for EPS and USD 1.45 billion for revenue.

That means EPS beat estimates by USD 1.46, while revenue came in USD 0.09 billion above forecasts. For investors, the comparison is the key point: the latest quarter added a fresh earnings beat to a stock that still trades below Jefferies' USD 1,215 target.

Stock stays near highs

Argenx stock was priced at USD 999.06 on September 17, 2026, leaving it 6.8 percent below the 52-week high of USD 1,072.75. The gap to that high matters more now than the daily move.